What is Sales and Marketing Strategy of SD BioSensor Company?

Government tenders, multilateral procurement and hospital GPOs delivered high‑volume, lower‑margin contracts that peaked in 2021–2022; in 2023–2024 management prioritized non‑COVID tenders as respiratory seasonality returned, reporting double‑digit growth in non‑COVID POCT volumes even while total revenue normalized.

A layered distributor network across LATAM, Africa, MENA and SEA handles registration, cold‑chain and last‑mile; regional exclusivities for STANDARD Q and STANDARD F helped the company rank among top rapid test suppliers in several LMIC markets by 2022–2023, shifting the channel mix from ~70–80% distributor‑led pre‑COVID to a more balanced split.

OTC antigen and self‑tests entered big‑box and pharmacy chains in mature markets via wholesale deals; retail volumes declined in 2023–2024 but remain strategic for flu/COVID combo self‑tests and women's health kits, offering higher per‑unit margins and sustained brand visibility.

Company webstore and major marketplaces supported replenishment and small clinics; DTC grew rapidly in 2021–2022, normalized thereafter, and in 2024–2025 saw increased compliance content and telehealth integration to boost conversion and regulatory adherence.

Emphasizes rapid, accurate, and affordable point‑of‑care tests that match laboratory reliability, targeting clinicians, public health buyers, and LMIC procurement agencies.

Clean clinical visuals, pragmatic evidence‑led tone, and prominent regulatory cues (WHO EUL/prequalification, CE/IVDR, relevant FDA listings) to signal quality and trust.

Broad POCT portfolio across infectious and chronic diseases, fast outbreak deployment capability, and a value leadership stance for LMICs without sacrificing performance.

Focus on ease‑of‑use, robust packaging, localized instructions for use (IFUs), and established distribution partners enabling rapid scale‑up and roll‑out.

Objective: rapid global awareness and adoption of COVID-19 antigen tests with the concept 'results in minutes, anywhere.' Channels combined institutional outreach, WHO/EUL communications, LinkedIn clinician content, distributor kits and retail how‑to videos. Results: secured large government tenders in 100+ countries, drove a peak revenue surge and widespread brand recognition; success drivers were regulatory validation, speed to supply and clear IFUs, with the lesson to balance consumer education and clinical procurement needs.

Objective: sustain OTC presence post‑pandemic and capture seasonal respiratory demand under 'one swab, clearer decisions.' Channels: pharmacy endcaps, e‑commerce PDP optimization, YouTube how‑to and earned media during flu peaks. Results: category share gains in select EU markets, improved DTC margins and higher basket size; success from timing with respiratory waves and simple visuals, with lessons on stock allocation and regional regulatory nuances.

Objective: expand in LMICs amid rising dengue incidence and sustained malaria programs, using 'fast detection saves community days.' Channels included NGO partnerships, medical missions, WhatsApp training modules, localized radio and CME webinars. Results: tender wins and higher distributor sell‑through in SEA/LATAM and uplift in non‑COVID revenue mix; success tied to disease‑burden targeting and localized training, with lesson that last‑mile education reduces invalid rates and returns.

Objective: penetrate hospital labs with immunoassay and molecular solutions via KOL‑led seminars and transparent performance data. Channels: AACC/ECCMID booths, white papers, LinkedIn Live and gated assets. Results: measurable pipeline growth in hospital accounts, multi‑analyte panel adoption and industry shortlists; success driven by a data‑first narrative and health‑economic framing.